(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the Poster Session A: Prostate Cancer. Dr. Moein Moradpour ...

The approval of ¹⁷⁷Lu-PSMA-617 for adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) previously treated with androgen receptor pathway inhibitors and ...

Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.

Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS ...

Genetically predicted rheumatoid arthritis is causally associated with prostate cancer, according to study findings.

Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) significantly improves overall survival in patients with metastatic ...

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

CariGenetics announced the “official update of its second major research initiative, the Caribbean Prostate Cancer Genetic ...

Real-world data highlight gaps in genetic testing and targeted therapy use for metastatic castration-resistant prostate ...

With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is ...

In the next in our series, GP Dr Roger Henderson debunks common myths about prostate cancer – and highlights some less ...

Pfizer (PFE) reported positive results from a Phase 3 study of Talzenna in combination with Xtandi in the treatment of ...